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Abstract
Objective In the current study, we propose an approach
for selection of a model that is transferable to a specific
decision-making context (in this case, the Netherlands),
using the case of rheumatoid arthritis (RA). The objec-
tives of this study were (a) to perform a systematic lit-
erature review to identify existing health economic
evaluation models for economic evaluation of disease-
modifying antirheumatic drugs (DMARDs) in RA; and
(b) to test the appropriateness of a stepwise model-
selection process.
Methods First, we searched Medline and Embase to
identify relevant studies in the English language,
published between 1 January 2002 and 31 August 2012.
From the included studies, all unique models were
identified. Second, we applied a multi-step approach to
model selection. Models that did not meet all minimal
methodological and structural requirements based on the
Outcome Measures in Rheumatology (OMERACT) cri-
teria were excluded. Next, models were assessed on the
basis of their fit when transferred to the Dutch health
care setting. The criteria for model fit were transfer-
ability factors, as published by Welte et al., after
exclusion of those that were deemed transferable by
simple adaptation. Finally, the remaining models under-
went a general quality check using the Philips checklist.
Models showing good fit and high quality were consid-
ered to be transferable to the Dutch health care setting,
using simple adaptation.
Results The systematic literature search identified 498
articles, which included 33 unique health economic eval-
uation models. Only six models passed the minimal
methodological and structural requirements. Two of these
models had an imperfect transferability fit to the Dutch
health care setting, according to the Welte method. The
remaining four models were, according to the Philips
method, of good quality and were expected to be trans-
ferable by a simple adaptation.
Conclusion This study introduces a stepwise approach
for selecting health economic evaluation models that are
transferable by a simple adaptation. The approach
seems feasible and can be applied in various therapeutic
areas, provided that the minimal methodological and
structural requirements are defined accordingly. Avail-
ability of health economic evaluation models coupled
with structured model selection could improve the
efficiency, quality and comparability of health economic
research.
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Key Points for Decision Makers
In health economic research, it is common practice
that health economic evaluation models are newly
developed to study a particular decision problem,
while suitable models may already exist from
previous research.
Prior to developing a new model, a structured
approach to identify existing models, and a stepwise
selection procedure to determine whether these
models could potentially be used to study the new
decision problem, could be applied.
Transparency in modelling methods and availability
of health economic evaluation models could lead to
more efficient, verifiable, comparable and qualitative
health economic research.
1 Introduction
Keeping health care affordable is increasingly challeng-
ing in many countries. Much attention is therefore
devoted to evaluating the balance between costs and
effects of health care innovation. Nowadays, the majority
of such economic evaluations are performed using health
economic evaluation models, in which sources of clinical
evidence, information on resource use, health care costs
and quality of life are synthesized in order to calculate
the incremental cost and effects associated with a certain
medical technology in comparison with an alternative.
By comparing multiple alternatives, important informa-
tion on the cost effectiveness of treatments can be
obtained. However, development of such health eco-
nomic evaluation models requires a great amount of time
and (technical) expertise.
In situations where health economic modelling is
required to support decision making, health economists
may face the choice to either develop a new model or
reuse an existing model. Although the latter option
sounds efficient, health economic evaluation models are
usually not directly generalizable to other jurisdictions,
because structural aspects, as well as the parameters of a
model, are often jurisdiction specific [1]. It may, how-
ever, be possible to transfer an existing model, i.e. to use
local data for estimation of model parameters, thereby
customizing the model to a local setting on the basis of
a simple adaptation [2]. The International Society For
Pharmacoeconomics and Outcomes Research (ISPOR)
Task Force on the Transferability of Economic Evalua-
tions Across Jurisdictions has suggested a stepwise
approach to support health economists to determine
whether simple or complex adaptation of a health eco-
nomic evaluation model to the jurisdiction of interest is
needed. In this approach, the potential models are
checked for their relevance to the decision problem,
methodological soundness and comparability of the
treatment patterns between the jurisdictions [2]. In
addition to this approach, several checklists have been
suggested in the literature to assess the transferability of
specific health economic evaluation results to other
jurisdictions [3]. One of these checklists is the decision
chart of Welte [4], which uses knock-out criteria to
determine whether transferring a model is impossible or
too difficult, and therefore whether conducting a new
study is a better option. Three general knock-out criteria
relate to the decision problem, the comparator and the
study quality, and 14 specific knock-out criteria consider
other aspects such as perspective, discount rate, prices
and practice variation.
While there are a considerable number of studies
focusing on assessing the transferability of a specific
model, little effort has been made to develop methods
for selecting the most suitable model among multiple
potentially transferable models, i.e. to select the model
that needs the simplest adaptation in order to be trans-
ferred to another jurisdiction. For example, one may be
interested in performing a health economic evaluation of
disease-modifying antirheumatic drugs (DMARDs) for
the treatment of rheumatoid arthritis (RA). As many
health economic evaluation models have been developed
for this purpose during the last 10 years—and as valid
models are highly important, given the increasing
complexity of treatment strategies and the advent of
several new but highly expensive drugs—it could be
worthwhile to investigate the transferability potential of
these models and to select a model that is most suitable
for simple adaptation to inform decisions in a specific
jurisdiction.
In the current study, we propose an approach for the
selection of a model that is transferable to a specific
decision-making context (in this case, the Netherlands),
using the case of synthetic and or biological disease-
modifying drugs in RA (see Box 1). The objectives of this
study were (a) to perform a systematic literature review to
identify existing health economic evaluation models for
the economic evaluation of DMARDs in RA; and (b) to
test the appropriateness of a stepwise model-selection
process.
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Box 1
Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an inflammatory joint dis-
ease, which is induced by immune intolerance. If
untreated, the resulting chronic synovial inflammation
causes destruction of the cartilage and erosions of the
articular bony surfaces, leading to joint deformity and
destruction. In Northern European countries, approxi-
mately 41 in every 100,000 people are diagnosed with RA
each year, the majority of whom are female [5, 6].
Although a curative treatment is still not available for RA,
a wide range of pharmacological therapies has become
available in recent decades, which can suppress inflam-
mation and even lead to remission, and can consequently
prevent further loss of joint tissues and functional decline
of the patients. The introduction of drugs that have all of
these properties—the so-called disease modifying anti-
rheumatic drugs (DMARDs)—has greatly improved the
quality of life of people with RA, especially the biological
DMARDs (bDMARDs) such as tumour necrosis factor
(TNF)-a inhibitors (i.a. etanercept, infliximab, ada-
limumab), abatacept and rituximab [7]. However, the
introduction of bDMARDs has also resulted in a steep
increase of treatment costs for RA, as bDMARDs have a
serious price tag [8]. This indicates the relevance of health
economic evaluation in RA, as governments and other
health care payers increasingly ask for justification of
these prices in terms of added clinical value.
Treatment of RA in the Netherlands
In the Netherlands, patients with RA receive specialized
care by rheumatologists. In order to prevent joint damage
and achieve clinical remission, treatment needs to be
timely and effective, striving for low disease activity.
Next to physiotherapy and exercise therapy, patients start
synthetic DMARD (sDMARD) therapy (the first-line
treatment is usually methotrexate) 6–12 weeks after dis-
ease onset. According to the usual ‘step-up’ strategy, a
combination of methotrexate and a bDMARD should be
considered only when a combination of two sDMARDs
remains ineffective. Adalimumab, infliximab or etaner-
cept are preferred as a second-line treatment, although
tocilizumab is also used as an initial bDMARD. Beyond
second-line treatment, different methotrexate/bDMARD
combinations (including abatacept and rituximab) should
be considered. Disease activity and progression are
strictly monitored during frequent outpatient visits
(
± every 3 months), and treatment regimens are adjusted
if necessary. In general, bDMARDs are discontinued if
there is no clinical response after 3 months of treatment.
2 Methods
2.1 Published Models
To identify published models for the economic evaluation
of DMARDs for the treatment of RA, we systematically
searched the Medline and Embase databases, as well as the
National Health Service Economic Evaluation Database
(NHS EED). Studies on modelling methodology and cost
effectiveness published in the English language between
1 January 2002 and 31 August 2012 were identified using a
range of search terms (see Appendix 1 in the Electronic
Supplementary Material). Our Medline search, in a short-
ened version, was as follows: ((rheumat* OR reumat*)
AND (arthrit* OR artrit*) AND (cost* OR economic* OR
pharmacoeconomic* OR (cost AND (analys* OR benefit
OR effectiveness OR utility))) AND (simulation OR
model* OR (decision AND (analys* OR analytic))) AND
(DMARD* OR antirheumatic* OR antireumatic* OR
biologic* OR TNF OR necrosis factor* OR *alpha OR
*alfa OR gold OR auranofin OR methotrexate OR MTX
OR cyclosporin OR ciclosporin OR *penicillamine OR
leflunomide OR azathioprine OR sulfasalazine OR SSZ OR
*chloroquine OR minocycline OR etanercept OR inflix-
imab OR adalimumab OR golimumab OR certolizumab
OR anakinra OR tocilizumab OR abatacept OR rituximab
OR tofacitinib)). The Embase search was conducted using
the same search terms as those used in Medline. In the NHS
EED, we used the broad search terms ‘rheumatoid’ AND
‘arthritis’ to ensure high sensitivity of the search. Refer-
ences of retrieved papers and other systematic reviews
were also checked to identify additional studies. Search
results were exported to Reference Manager Professional
Edition Version 12 software (Thomson Reuters, New York,
NY, USA), and duplicate articles were removed.
The title and abstract of all retrieved studies were inde-
pendently scanned by two reviewers (HvH and JS or ATD)
on the basis of the following exclusion criteria: (1) no pri-
mary data (e.g. review papers, editorials, comments); (2) no
adult study population with RA; (3) no study population
starting/on DMARDs; (4) no use of a model for cost-effec-
tiveness evaluation of DMARD therapy; (5) no examination
of both cost and consequences; and (6) no associated pub-
lished full text. These exclusion criteria were not applied to
methodological papers on the development of a health eco-
nomic evaluation model for DMARDs in RA, i.e. these
papers were included regardless of whether or not they
reported a specific patient population or simulation results. In
cases of disagreement between reviewers, both reviewers
read and discussed the full text in order to reach a consensus.
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After the title and abstract scan, the full texts of the
included papers were reviewed by two independent authors
(HvH and JS or ATD) using the same exclusion and
inclusion criteria as mentioned above. In order to select a
series of unique models, multiple papers based on the same
model were clustered as one case. The study selection
process, including assessment of exclusion and inclusion
criteria, was systematically recorded in a spreadsheet and
presented by a flow chart.
2.2 Selecting a Transferable Model
2.2.1 Step 1: Which Models Are Suitable?
As the first step in determining which models are poten-
tially suitable to be transferred, we assessed the conceptual
validity of the identified models, i.e. whether the individual
models adequately represented the concept of the disease
and its clinical context in their modelling framework. For
this purpose, it was necessary to specify a list of disease-
specific minimal methodological and structural require-
ments that were considered important for securing the
conceptual validity of health economic evaluation models.
In the case of RA, such requirements were previously
specified by the Outcome Measures in Rheumatology
(OMERACT) Group, which is an international organiza-
tion of clinicians, researchers, methodologists, patients and
industrial partners aiming at standardizing outcomes,
including economic outcomes in rheumatologic diseases
[9]. In 2003, the OMERACT Group published a consensus-
based reference case on health economic modelling
methods in RA, in which several methodological topics
were discussed and guidance was provided on the preferred
modelling methodology for each topic if a consensus was
reached [9]. This OMERACT reference case served as a
basis for our requirements. We selected those topics from
the reference case that concerned conceptual validity of
health economic evaluation models and for which a clear
guidance was provided.
Additional methodological guidance on modelling
methods in RA was provided in later publications by
Bansback et al. [10, 11]. This guidance was considered to
be supplemental to the OMERACT guidance and was
therefore also adopted in our requirements. The final set of
minimal methodological and structural requirements that
was applied is summarized in Table 1. According to the
OMERACT criteria, authors should clearly define the study
population for which the model is developed, because
clinical inputs, as well as the model structure, are often
specific to a certain RA subpopulation, such as patients
who do not respond to a synthetic DMARD (sDMARD) or
a tumour necrosis factor (TNF)-a inhibitor [9]. Secondly,
realistic treatment sequences should be modelled, as RA
treatment in clinical practice includes a sequence of agents
rather than a single agent [9]. Although OMERACT does
not state this explicitly, the authors agreed that the
sequence needed to consist of consecutive specific treat-
ments rather than applying a subsequent treatment line
consisting of several pooled treatments, as the clinical
response to various treatment options could be influenced
by previous therapy lines, and unique treatments are more
adjustable. Third, as advised by Bansback et al. [11],
withdrawal of therapy within the model should be due to
lack of efficacy or severe toxicity, rather than keeping all
subjects on treatment until the end of the simulation or
until a specific point in time during the simulation. Such
withdrawal schemes do not reflect clinical practice and
could therefore jeopardize the validity of the simulation.
Next, the models should meet the following criteria: the
time horizon is at least 1 year, with the possibility to
extrapolate beyond this period; mortality is accounted for
in the simulation [9]; and QALYs are used as a measure of
Table 1 Minimal methodological and structural requirements for securing conceptual validity
Requirements Based on
1. A clear definition of the underlying population should be included OMERACT [9]
2. Realistic (and explicit) treatment sequences should be modelled, depending on the clinical setting and the baseline
characteristics of the patients
OMERACT [9, 11] and
Bansback [9, 11]
3. Withdrawal due to lack of efficacy or severe toxicity should be modelled (i.e. a patient should not remain on a
specific drug until the end of the simulation)
Bansback [11]
4. Models should include at least a 1-year time horizon, with the possibility to extrapolate beyond this period OMERACT [9]
5. The risk of mortality should be included OMERACT [9]
6. QALYs should be reported in combination with disease-specific outcome measures (e.g. ACR20, improvement in
DAS or HAQ score)
OMERACT [9]
7. Clinical response should be defined using absolute health outcomes (DAS or HAQ score) rather than relative
health outcomes (ACR response)
Bansback [10]
ACR American College of Rheumatology, DAS Disease Activity Score, HAQ Health Assessment Questionnaire, OMERACT Outcome Measures
in Rheumatology, QALY quality-adjusted life-year
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effectiveness to enable comparisons of cost-effectiveness
outcomes across therapeutic areas [9].
Finally, it was required that progression through the
model is induced by absolute changes in the subject’s
disease status—using, for example, the Health Assessment
Questionnaire (HAQ) score or the Disease Activity Score
(DAS)1 [10]. On this line, American College of Rheuma-
tology (ACR) responses are considered unsuitable to define
transition probabilities, as in clinical practice, (dis)contin-
uation decisions are unlikely to be informed by ACR
response and such models are therefore unlikely to reflect
reality [10]. Also subjects’ disease status within the model,
which informs estimates of resource utilization (costs) and
utilities, should not be defined by ACR response status, as
this reflects a relative improvement rather than the actual
disease status of a patient [10].
Positive assessment based on full information on each
criterion was required for selection of a model. Thus, if a
model did not meet all criteria, it was excluded. Model
selection was performed by one reviewer (HvH), and
exclusion of models was verified by a second reviewer
(JS).
2.2.2 Step 2: Which Models Fit?
Next, we specified a list of criteria to assess the model fit,
thereby evaluating whether the model structure is appro-
priate in the context of a particular health care setting. The
Dutch health care setting was used as an illustrative case.
These criteria were based on the ‘specific knock-out cri-
teria’ proposed by Welte et al. [4]. We distinguished
between specific knock-out criteria that concerned param-
eter or structural uncertainty within a model. Parameter
uncertainty relates to the uncertainty surrounding the input
data and probabilities that govern the outcomes because of,
for example, multiple (conflicting) studies, lack of internal
or external validity of the study data, or lack of data [12].
Structural uncertainty is present when there is uncertainty
about the functional form of the model, i.e. whether the
model adequately reflects reality surrounding the decision
problem. Generally, in the presence of structural uncer-
tainty, one cannot be certain that the produced results are
valid, even if the true values of all input parameters are
known [12].
We defined performing a ‘simple’ adaptation of a health
economic evaluation model as minimizing the parameter
uncertainty by adapting those input values that are subject
to bias when transferring the model. In this regard, when
selecting a model, there seems to be no need for exclusion
of a model on the basis of parameter uncertainty, as this
can be addressed during the simple adaptation process. In
general, it is more difficult to adapt structural uncertainty,
as this often requires technical amendments to the model.
Therefore, selecting a model with limited structural
uncertainty would facilitate a simple model adaptation.
On the basis of this theory, we assessed which of
Welte’s specific knock-out criteria related to parameter
uncertainty and which related to structural uncertainty
within a model. The result of this assessment is presented
in Table 2 (see Appendix 2 in the Electronic Supplemen-
tary Material for the rationale). Next, studies were exclu-
ded merely on the basis of the criteria that concerned
structural uncertainty.
2.2.3 Step 3: Which Model Is Best?
In order to know which of the eligible models has the
highest quality, models that passed step 2 were additionally
assessed on general methodological quality, on the basis of
the Philips checklist [13]. Using the Philips checklist, the
models are, among other criteria, evaluated on the sub-
stantiation of the applied methodology, the model func-
tionality, the mathematical logic and the external validity.
To our knowledge, the Philips checklist is a very suitable
general quality checklist for health economic modelling
studies, although minor overlap between the Philips criteria
and the minimal methodological and structural require-
ments is present (e.g. criteria S7 and S8). As the Philips
criteria can be applied to all health economic evaluation
studies regardless of disease area, the criteria are
1 Some models use survival statistics based on observational data to
predict the subjects’ time on treatment. We also considered this a
suitable approach for modelling health state transitions (i.e. treatment
discontinuation).
Table 2 Categorization of Welte’s transferability factors
Transferability factors Parameter
uncertainty
Structural
uncertainty
Perspective 4 –
Discount rate 4 –
Medical cost approach 4 –
Productivity cost approach 4 –
Absolute and relative prices 4 –
Practice variation 4 4
Technology availability 4 4
Disease incidence/prevalence 4 –
Case mix 4 4
Life expectancy 4 –
Health status preferences 4 –
Acceptance, compliance and
incentives for patients
4 –
Productivity and absenteeism 4 –
Disease spread 4 4
4 uncertainty applicable, – uncertainty not applicable
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formulated in general terms—for example, ‘is the time
horizon of the model sufficient (…)?’ [13]. What time
horizon is sufficient in the case of RA has been defined by
OMERACT and is reflected in the minimal methodological
and structural requirements. Thus, models that have passed
the minimal methodological and structural requirements
will, by definition, pass the overlapping Philips criteria as
well.
3 Results
3.1 Published Models
The systematic literature search identified 498 articles, of
which 55 articles were initially selected for full-text review
after the title and abstract scan (Fig. 1). After review of the
full texts, eight articles were additionally excluded either
because they appeared to be abstracts (2) or duplicates (3),
or because no model was used (2). One full paper could not
be retrieved [14]. Two papers were added to the list as a
result of additional reference screening. This resulted in 49
included papers, from which 33 unique health economic
evaluation models were identified (as some papers con-
cerned the same model). The defined model clusters are
presented in Table 3.
3.2 Selecting a Transferable Model
3.2.1 Step 1: Which Models Are Suitable?
Out of the 33 unique models, only six models passed the
minimal methodological and structural requirements [17,
24, 29, 38, 39, 54]. Ten models did not pass the require-
ment on treatment sequence and/or withdrawal; these
models assumed either treatment discontinuation at a fixed
point in time [32, 62], no subsequent treatment [25, 26],
switching to a single DMARD therapy for the remainder of
the time horizon after treatment discontinuation (i.e. not a
realistic treatment sequence) [42, 44, 55, 58] or a sub-
sequent therapy line consisting of ‘pooled’ therapies, which
were non-explicit [32, 50]. Three models did not include
the possibility to extrapolate beyond a time horizon of
1 year [25, 26, 37], whereas 12 models did not simulate the
mortality of the patients [16, 25, 26, 41, 45–48, 51, 53, 59].
Six models did not report quality-adjusted life-years
(QALYs) as an outcome [16, 26, 45–47, 51] and, finally, 15
models did not use absolute health outcomes to define
health states or to define transitions through the model [15,
23, 25–28, 30, 31, 41, 43, 44, 48, 49, 52, 53]. Thirteen
models were excluded because they did not meet multiple
requirements, leaving six models with adequate conceptual
validity to pass through to the next step.
3.2.2 Step 2: Which Models Fit?
The models by Kobelt et al. in 2011 [38] and Finckh et al.
[29] were excluded on the basis of the specific knock-out
criteria. Potential case-mix bias (due to differences in
patient populations and therefore possible differences in
treatment responses [4]) can be avoided when transferring
these models through adaptation of the parameter inputs.
However, the cycle length of 6 months used in both models
could introduce practice variation bias when transferring
them because in the Netherlands, the follow-up interval is
generally 3 months, and so a cycle length of 3 months
would have been more appropriate [29, 38].
Brennan et al. [24] used observational data from the
British Society for Rheumatology Biologics Registry
(BSRBR) to construct regression models for prediction of
the European League Against Rheumatism (EULAR)
response (a measure of treatment effect), impact on health
utility, time on treatment and hospital stay on the basis of
various patient and disease characteristics. Lindgren et al.
[39] and Kobelt et al. [40] used a similar approach in their
models (referred to as the ‘Lindgren cluster’), in which
they used data from the Southern Swedish Arthritis
Treatment Group (SSATG) Register to predict time on
treatment, time to treatment re-initiation and HAQ pro-
gression. Although the model predictions can be adjusted
for important covariates, bias could be introduced in the
transferred model if the population and clinical practice
characteristics underlying the models for UK and Sweden
differ from those for the Netherlands. For those simulated
results that are deemed not comparable between the juris-
dictions, new data analysis and adjustment of the prediction
models, using Dutch-specific observational data, are nec-
essary to avoid uncertainty due to case-mix and practiceFig. 1 Flow diagram of search results
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variation. The adjustment of these models can be regarded
as a simple adaptation, and therefore these models are not
excluded.
The Birmingham Rheumatoid Arthritis Model (BRAM)
was developed for the purpose of a multiple technology
appraisal program, commissioned by the National Institute
for Health and Care Excellence (NICE), and was designed
to be flexible in changing interventions and treatment
sequences in RA [18]. The individual sampling model was
populated with UK data, but these can be replaced by local
data. In addition, the model has an option to specify stages
of early withdrawal, thereby enabling treatment discon-
tinuation within a certain number of weeks of treatment in
accordance with local clinical practice. It seems therefore
Table 3 Results of applying the general knock-out criteria
Author/model
cluster
Year Reference Country Minimal methodological and structural requirements
Population Sequence Withdrawal Time
horizon
Mortality QALYs Absolute
outcomes
Bansback 2005 [15] Sweden 4 4 4 4 4 4 –
Beresniak 2011 [16] Spain 4 4 4 4 – – 4
BRAM cluster 2002–2011 [17–22] UK 4 4 4 4 4 4 4
Brennan 2004 [23] UK 4 4 4 4 4 4 –
Brennan 2007 [24] UK 4 4 4 4 4 4 4
Chiou 2004 [25] US – – – – – 4 –
Choi 2002 [26] US 4 – – – – – –
Davies 2009 [27] US 4 4 4 4 4 4 –
Diamantopoulos 2012 [28] Italy 4 4 4 4 – 4 –
Finckh 2009 [29] US 4 4 4 4 4 4 4
Hallinen 2010 [30] Finland 4 4 4 4 4 4 –
Kielhorn 2008 [31] UK 4 4 4 4 4 4 –
Kobelt cluster 2002–2010 [32–37] Sweden and UK 4 – – 4 4 4 4
Kobelt 2011 [38] Sweden 4 4 4 4 4 4 4
Lindgren cluster 2009 [39, 40] Sweden 4 4 4 4 4 4 4
Maetzel 2002 [41] Canada 4 4 4 4 – 4 –
Marra 2007 [42] Canada 4 – 4 4 4 4 4
Merkesdal 2010 [43] Germany 4 4 4 4 4 4 –
Nguyen 2012 [44] US 4 – 4 4 4 4 –
Puolakka 2012 [45] Finland 4 4 4 4 – – 4
Russell 2009 [46] Canada 4 4 4 4 – – 4
Saraux 2010 [47] France 4 4 4 4 – – 4
Schadlich 2005 [48] Germany 4 4 4 4 – 4 –
Soini 2012 [49] Finland 4 4 4 4 4 4 –
Spalding 2006 [50] US 4 – 4 4 4 4 4
Suka 2004 [51] Japan 4 – – – – – 4
Tanno 2006 [52] Japan 4 4 4 4 4 4 –
Tosh 2011 [53] UK 4 4 4 4 – 4 –
Tosh–Sheffield
model
2011 [54] UK 4 4 4a 4 4 4 4
Vera-Llonch
cluster
2008–2010 [55–57] US 4 – 4 4 4 4 4
Wailoo 2008 [58] US 4 – 4 4 4 4 4
Welsing cluster 2004–2011 [59–61] Netherlands 4 4 4 4 – 4 4
Wong cluster 2002–2005 [62, 63] US and UK 4 4 – 4 4 4 4
BRAM Birmingham Rheumatoid Arthritis Model, QALY quality-adjusted life-year, 4 requirement met, – requirement not met
a Not all required information is mentioned in the referred paper. From other papers that have used/adapted the Sheffield model, we understand
that all criteria can theoretically be fulfilled [15, 23, 39, 47]. However, these models were regarded as unsuitable for clustering, as each model
contains different structural adaptations
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that the risk of case-mix or practice variation bias after a
simple adaptation procedure is limited with this model.
Like the BRAM, the Sheffield model is a model that has
been adapted several times and used for various research
purposes over the years [54]. Some of the models included
in this review—for example, the model by Brennan et al.
[24]—are descendants of the Sheffield model but, as a
result of different structural adaptations, the modelling
methods have diverged, making these models not identical
and therefore difficult to cluster. The general Sheffield
model, as described by Tosh et al. [54], is flexible in terms
of evaluating different patient populations and is able to
utilize a wide range of data types. On the basis of this
flexibility and the key inputs that are required by the model
(initial effectiveness, HAQ progression while on treatment
and length of treatment), it seems that the model is suffi-
ciently adaptable to prevent case-mix or practice variation
bias in the transferred model. However, the general model
structure has been described very briefly, and therefore it is
difficult to assess the complexity of the adaptation process.
The specific knock-out criterion ‘technology availabil-
ity’ was not considered a risk for structural bias when
transferring any of the models. The therapeutic technolo-
gies of interest in this case (in the treatment of RA) mainly
concern drugs and medical personnel, which are not
expected to differ much between the UK/Sweden and the
Netherlands. The criterion ‘disease spread’ was not appli-
cable to the case of RA and was therefore not considered.
The result of the assessment is presented in Table 4.
3.2.3 Step 3: Which Model Is Best?
The BRAM, as well as the model by Brennan, appeared to
have the highest quality according to the Philips checklist
(Table 5). However, many criteria focused on the reports of
the study and the model inputs, rather than the model
structure. As model inputs are adaptable, the criteria
looking at the model structure may be considered more
relevant. Looking more specifically at the criteria of the
model structure, all four remaining models were considered
of good quality and suitable for simple adaptation [18, 24,
39, 54].
The choice of one of the models may eventually depend
on specific model characteristics, data availability and user
preferences. A comparison of modelling methods in more
detail may consolidate the choice. The basic structures of
the four suitable models are relatively similar; they are all
individual sampling models consisting of multiple treat-
ment lines; they use HAQ progression as the clinical out-
come, they define treatment switching on the basis of the
time on treatment or time to an event, and they link the
quality of life to HAQ scores. However, differences are
also present. For example, only the model by Lindgren
et al. includes DAS in addition to HAQ scores to define its
health states. The models by Lindgren et al. and Brennan
et al. are based on data from observational studies, whereas
the BRAM and Sheffield models are based on data derived
from clinical trials. Brennan et al. include only direct costs
related to treatment, whereas the other models also include
costs of resource use linked to disease severity. Both
Lindgren et al. and the BRAM model apply mortality rates
on the basis of disease severity, while the other models
apply standard life tables. In the Netherlands, DAS, next to
HAQ scores, is considered to be a relevant outcome mea-
sure, and patient-level observational data on these out-
comes and on quality of life (QoL) outcomes are available.
Therefore, the model by Lindgren et al. seems to be a good
choice for the Netherlands.
4 Discussion
In this study, we performed a stepwise process for the
selection of a health economic evaluation model that is
suitable for simple adaptation. We found that six models
fulfilled the pre-specified minimal methodological and
structural requirements, of which four models seemed to
have the best fit with the Dutch health care setting, and all
four were of good quality. These models were therefore
regarded as suitable to transfer by a simple adaptation.
To our knowledge, no examples of similar model
selection exercises are available in the literature. Although
it is common practice that health economic evaluation
models are newly developed for specific decision prob-
lems, there are also many examples of models that have
been adapted and re-used for multiple purposes within
multiple countries. Often this occurred within research
groups who developed a model and used this model mul-
tiple times to answer different research questions (such as
the studies performed by Kobelt et al. [32–37]). Apart from
Table 4 Results of applying the specific knock-out criteria
Model Specific knock-out criteria
Practice
variation
Technology
availability
Case
mix
BRAM cluster [17–22] Good fit Good fit Good fit
Brennan [24] Good fit Good fit Good fit
Finckh [29] Imperfect fit Good fit Good fit
Kobelt [38] Imperfect fit Good fit Good fit
Lindgren cluster [39, 40] Good fit Good fit Good fit
Tosh–Sheffield model [54] Good fit Good fit Good fit
The criterion ‘disease spread’ was left out of the table, as this is not
applicable for rheumatoid arthritis models
BRAM Birmingham Rheumatoid Arthritis Model
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Table 5 Results of applying the Philips quality checklist
Philips criteria BRAMa
[17–22]
Brennan
[24]
Lindgren
[39, 40]
Sheffield
[54]
Structure
S1 Is there a clear statement of the decision problem? Yes Yes Yes NA
Is the objective specified and consistent with the stated decision problem? Yes Yes Yes NA
Is the primary decision maker specified? Yes Yes No NA
S2 Is the perspective of the model stated clearly? Yes Yes Yes NA
Are the model inputs consistent with the stated perspective? Yes Yes Yes NA
Has the scope of the model been stated and justified? Yes Yes Yes NA
Are the outcomes of the model consistent with the perspective, scope and overall
objective of the model?
Yes Yes Yes NA
S3 Has the evidence regarding the model structure been described? Yes Yes Yes Yes
Are the sources of data used to develop the structure of the model specified? No No No No
Are the causal relationships described by the model structure justified appropriately? Yes Yes Yes Yes
S4 Are the structural assumptions transparent and justified? Yes Yes Yes Yes/No
Are the structural assumptions reasonable given the overall objective, perspective and
scope of the model?
Yes Yes Yes Yes
S5 Is there a clear definition of the options under evaluation? Yes Yes Yes NA
Have all feasible and practical options been evaluated? Yes Yes Yes NA
Is there justification for the exclusion of feasible options? NA NA NA NA
S6 Is the chosen model type appropriate given the decision problem and specified causal
relationships within the model?
Yes Yes Yes Yes
S7 Is the time horizon of the model sufficient to reflect all important differences between
options?
Yes Yes Yes Yes
Is the time horizon of the model, the duration of treatment and the duration of treatment
effect described and justified?
Yes Yes Yes Yes
S8 Do the disease states (state transition model) or the pathways (decision tree model)
reflect the underlying biological process of the disease in question and the impact of
interventions?
Yes Yes Yes Yes
S9 Is the cycle length defined and justified in terms of the natural history of disease? NA NA NA NA
Data
D1 Are the data identification methods transparent and appropriate given the objectives of
the model?
Yes Yes Yes NA
Where choices have been made between data sources, are these justified appropriately? Yes Yes Yes NA
Has particular attention been paid to identifying data for the important parameters in the
model?
Yes Yes Yes NA
Has the process of selecting key parameters been justified and systematic methods used
to identify the most appropriate data?
Yes Yes Yes NA
Has the quality of the data been assessed appropriately? Yes Yes Yes NA
Where expert opinion has been used, are the methods described and justified? NA NA NA NA
D2 Is the pre-model data analysis methodology based on justifiable statistical and
epidemiological techniques?
Yes Yes Yes/No NA
D2a Is the choice of baseline data described and justified? Yes Yes Yes NA
Are transition probabilities calculated appropriately? Yes Yes Yes NA
Has a half cycle correction been applied to both cost and outcome? NA NA NA NA
If not, has this omission been justified? NA NA NA NA
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the model developers, parties such as industry also used
existing models to perform health economic research (for
example, the Center for Outcomes Research & Evaluation
[CORE] diabetes model) [64]. Especially in therapeutic
areas such as RA and diabetes, where high-quality health
economic evaluation models have been developed over the
years, it can be a challenge to develop a model that
approaches the quality of some of the existing models.
Adapting a good-quality model may be an efficient use of
resources, provided that the model fits well for the juris-
diction of interest. We believe that a systematic and
explicit approach for model selection can contribute to the
validity of the study results when existing models are
adapted to study new decision problems.
Table 5 continued
Philips criteria BRAMa
[17–22]
Brennan
[24]
Lindgren
[39, 40]
Sheffield
[54]
D2b If relative treatment effects have been derived from trial data, have they been
synthesized using appropriate techniques?
Yes/No Yes Yes/No NA
Have the methods and assumptions used to extrapolate short-term results to final
outcomes been documented and justified?
Yes Yes Yes Yes
Have alternative extrapolation assumptions been explored through sensitivity analysis? Yes Yes Yes/No NA
Have assumptions regarding the continuing effect of treatment once treatment is
complete been documented and justified?
Yes Yes Yes Yes
Have alternative assumptions regarding the continuing effect of treatment been
explored through sensitivity analysis?
No Yes Yes NA
D2c Are the utilities incorporated into the model appropriate? Yes Yes Yes NA
Is the source for the utility weights referenced? Yes Yes Yes NA
Are the methods of derivation for the utility weights justified? Yes Yes Yes NA
D3 Have all data incorporated into the model been described and referenced in sufficient
detail?
Yes Yes/No No NA
Has the use of mutually inconsistent data been justified (i.e. are assumptions and
choices appropriate?)
NA NA Yes/No NA
Is the process of data incorporation transparent? Yes Yes Yes NA
If data have been incorporated as distributions, has the choice of distribution for each
parameter been described and justified?
Yes/No No No NA
If data have been incorporated as distributions, is it clear that second-order uncertainty
is reflected?
Yes Yes Yes NA
D4 Have the four principal types of uncertainty been addressed? Yes Yes Yes NA
If not, has the omission of particular forms of uncertainty been justified? NA NA NA NA
D4a Have methodological uncertainties been addressed by running alternative versions of
the model with different methodological assumptions?
Yes Yes Yes NA
D4b Is there evidence that structural uncertainties have been addressed via sensitivity
analysis?
Yes Yes Yes NA
D4c Has heterogeneity been dealt with by running the model separately for different
subgroups?
No Yes Yes NA
D4d Are the methods of assessment of parameter uncertainty appropriate? Yes Yes Yes NA
If data are incorporated as point estimates, are the ranges used for sensitivity analysis
stated clearly and justified?
Yes/No NA No NA
Consistency
C1 Is there evidence that the mathematical logic of the model has been tested thoroughly
before use?
No No No No
C2 Are the conclusions valid given the data presented? Yes Yes Yes NA
Are any counterintuitive results from the model explained and justified? NA NA NA NA
If the model has been calibrated against independent data, have any differences been
explained and justified?
NA NA NA NA
Have the results of the model been compared with those of previous models and any
differences in results explained?
Yes Yes No NA
BRAM Birmingham Rheumatoid Arthritis Model, NA criterion not applicable, Yes/No answer is debatable
a Malottki et al., 2011 [17], Barton et al., 2011 [19]
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The methodology we chose for this exercise was pre-
defined and was based mainly on the ISPOR Good
Research Practices on the Transferability of Economic
Evaluations Across Jurisdictions [2] and on the decision
chart of Welte [4]. The decision chart of Welte starts with
three ‘general knock-out criteria’, which concern the
evaluated technology, the comparator and the study qual-
ity. The criterion of study quality was adopted in our
approach but was, for reasons of logic and efficiency,
redefined to be our last step. Because Welte did not specify
the method for the assessment of study quality, we pro-
posed to apply the Philips checklist, which is quite elabo-
rate. The general knock-out criteria ‘evaluated technology’
and ‘comparator’ were not adopted in our approach for the
following reasons. First, models that include a treatment or
comparator different from that in the research question of
interest may be perfectly suitable to be (simply) adapted to
include the treatment or comparator of interest. Second, if
only models that include a specific treatment or comparator
are to be considered, such models can be selected by
specifying the inclusion and exclusion criteria in the sys-
tematic literature search. Third, if the treatment or com-
parator of interest requires specific methodological/
structural model features, these can be specified in the
‘minimal methodological requirements’ of step 1 of the
selection process.
Conceptual validity is of major importance when
selecting a health economic evaluation model, as this
secures a fair representation of the treatment and contextual
reality. For the case of RA, the OMERACT reference case
was regarded as the most suitable guidance for defining the
requirements to determine conceptual validity and there-
fore served as the basis for these criteria. However, the
criteria may have been too strict because in some cases, the
excluded models met most of the criteria and the failed
criterion might have been overcome if the model had been
transferred (e.g. it probably would not have been very
complicated to adapt the model by Welsing et al. [60] to
include mortality). We also encountered one study that
reported disability-adjusted life-years (DALYs) instead of
QALYs, and it was (for this and other reasons) excluded
[51]. Although DALYs are not mentioned by OMERACT
as a relevant outcome, DALYs can be a valid outcome
measure for health economic evaluations.
For future application, it is advisable to specify the
minimal methodological and structural requirements based
on the available evidence of good methodological practice
in the therapeutic area of interest. The OMERACT refer-
ence case serves as a good example of such evidence, and it
would be useful if such exercises were also undertaken in
other disease areas to derive consensus-based criteria, as
has previously been proposed within the field of osteoar-
thritis [65]. If such a reference case is not available, it may
be worthwhile to search for other sources of guidance—for
example, from methodological publications on health
economic modelling or from previous literature reviews of
models in the therapeutic area of interest. Also, it may be
necessary to account for the specific research question
when specifying the requirements—for example, if a cer-
tain intervention requires specific structural or functional
modelling options. In addition, the minimal methodologi-
cal and structural requirements should be customized to the
jurisdiction to which the model will be transferred, as many
jurisdictions have their own guidelines when it comes to
health economic research (e.g. on the time horizon of the
analysis), and the model should be able to produce all
required results. Naturally, the outcome of the selection
process also very much depends on the jurisdiction of
interest—for example, where Swedish models may show a
relatively good fit when transferred to the Netherlands,
these models will probably show a poor fit when trans-
ferred to a jurisdiction where health care practice is very
different. Had we taken another country as an illustrative
case, other models would possibly have passed our selec-
tion criteria, resulting in a different set of selected models.
It is questionable whether applying a different order of
selection steps is more appropriate. We could have
reversed steps 2 and 3, thereby applying the Philips
checklist prior to the specific knock-out criteria for model
fit. However, the Philips checklist does not have a clear
cut-off point between good and poor quality, making model
selection difficult. In addition, on the basis of our experi-
ence, it takes much more time to go through the Philips
checklist (±3 h) than to go through the specific knock-out
criteria (±30 min), and it is therefore more pragmatic to
apply the Philips checklist as a last step. Another concern is
that the total time required to conduct this selection pro-
cedure might be longer than that needed to develop a new
model. However, even if the modelling time is shorter
(which is almost impossible to affirm prior to conducting
the selection procedure), knowledge of the existing models
and previously applied methodology is valuable and can be
considered a starting point for developing a new (prefera-
bly superior) model. In any case, the currently proposed
procedure is helpful, especially in justifying the researcher
decision on whether or not a new model should be devel-
oped. We thus conclude that our proposed selection process
is appropriate and feasible.
A limitation of the current exercise is that it was not
possible to assess the computerized model validity, as the
modelling codes were not published. This reflects a sig-
nificant problem for researchers who want to use an
existing health economic evaluation model—namely, that
most models are not easily available to others than those
who developed it. Generally, models are regarded as the
intellectual property of the developer, which is
How to Select the Right Cost-Effectiveness Model? 439
understandable given that it may take months to years of
work for the models to be developed. This makes model
selection complicated, as detailed descriptions of the model
are not always provided in the papers and the model soft-
ware is usually not published. Without access to the
models, the assessment of the model fit is also subject to
uncertainty, as it is impossible to describe all methodo-
logical details in a paper. Furthermore, once the selection
process is completed, the possibility to transfer the model
depends on the willingness of the model owner to provide
access to the model and to permit the use of it.
Availability of (or access to) the model is required in
order to successfully transfer health economic evaluation
models. Broad availability of models could improve the
efficiency of health economic research and the quality of
the models and the resulting health economic evidence, as
researchers could cooperate and provide feedback on each
other’s work. In addition, it would become much easier to
assess the validity of health economic evidence, and it
would make health economic studies more reproducible—a
general prerequisite in scientific research [66]. If this ideal
situation is established, transferring models will be highly
possible in the context of scientific cooperation, under
licensing conditions or by other financial arrangements.
Some models are already open source, such as the Evi-
dence-Based Medicine Integrator simulator for type 2
diabetes mellitus [67] and the Comprehensive Discrete
Event Simulation Model for Major Depressive Disorder,
developed by Toumi et al. [68].
5 Conclusion
Overall, we conclude that, prior to development of a new
health economic evaluation model for a specific decision
problem, application of a systematic approach to identifi-
cation of existing models—and selection of a qualitative
model that is transferable—is feasible and is expected to
contribute to the efficiency, quality and validity of the
resulting health economic evidence.
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